




RealRate

PHARMACEUTICAL 2022

Bioxcel Therapeutics Inc
Rank 120 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Bioxcel Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bioxcel Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 113% points. The greatest weakness of Bioxcel Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 364%, being 89% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	236,812
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,667
Liabilities, Non-Current	1,105
Other Assets	1,333
Other Compr. Net Income	0
Other Expenses	40
Other Liabilities	0
Other Net Income	44
Other Revenues	0
Property and Equipment	1,294
Research and Development	52,708
Selling, General and Administrative Expense	54,227

Output Variable	Value in 1000 USD
Assets	239,439
Liabilities	17,772
Expenses	106,975
Revenues	0
Stockholders Equity	221,667
Net Income	-106,931
Comprehensive Net Income	-106,931
BaseVar	182,115
ECR before Limited Liability	293%
Economic Capital Ratio	364%